Background: An exploratory translational analysis was conducted as part of a phase II study of dovitinib to assess the relevance of soluble serum proteins and circulating tumor (ct) DNA (ctDNA) as biomarkers in patients with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GISTs).
introduction
The standard therapy for inoperable locally advanced and metastatic gastrointestinal stromal tumors (GISTs) consists of imatinib and sunitinib [1] . A number of novel agents have been investigated for activity against imatinib/sunitinib-refractory GISTs; however, most of these drugs have failed to demonstrate efficacy in randomized trials [1, 2] . Before the results of the phase III trial favoring regorafenib as a third-line therapy in GISTs were available [2] , we carried out a phase II trial of dovitinib, a novel tyrosine kinase inhibitor (TKI) targeting c-KIT, fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor β (PDGFRβ) for patients with TKI-refractory GISTs [3] . In that study, dovitinib exhibited modest anticancer activity and a tolerable safety profile.
Identifying biomarkers that define patient subgroups that do benefit from dovitinib may provide further insight into its mechanism of action against GISTs and help refine our approach to future clinical trials. Therefore, an exploratory translational analysis was carried out for patients enrolled in the previous phase II study of dovitinib. As the main mechanism of action of dovitinib is thought to be antiangiogenic, soluble serum protein markers involved in the VEGF and FGF pathways were examined. Dovitinib activity may also be related to tumor genotype. Most GISTs harbor activating mutations in KIT or PDGFRα, and previous studies have shown that these mutations are associated with clinical outcome with both imatinib and sunitinib. Clonal evolution of GISTs harboring secondary kinase mutations results in acquired resistance to TKIs. As secondary mutations develop polyclonally, inter-and/or intratumoral heterogeneity may exist in each patient, particularly in those with advanced disease and multiple treatment failures. Although genotyping of tumor tissue is the gold standard method for detection of mutations, its utility is relatively limited in a salvage setting [4] , considering the risk of complications associated with the invasive biopsy procedure and the potential failure to fully assess the molecular heterogeneity of the tumor. We therefore carried out mutational analysis on circulating tumor (ct) DNA (ctDNA) in serum using a novel technique, BEAMing (Beads, Emulsions, Amplification, and Magnetics) [5] .
methods patients
All 30 patients with TKI-refractory GISTs enrolled in the prior phase II study [3] were included in this biomarker analysis. Patients received oral dovitinib (500 mg) once daily on a 5 days-on/2 days-off schedule with a 28-day cycle.
The study was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea, and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Informed consent for serum protein biomarker analysis was obtained before enrollment in the phase II study of dovitinib, and informed consent for the mutation analysis of ctDNA was additionally obtained for all patients.
serum protein biomarkers
Predose serum samples were collected on day 1 of cycle 1 (n = 30) and cycle 2 (n = 28). Enzyme-linked immunosorbent assays (ELISA) were used to assess serum levels of each soluble protein. Candidate protein biomarkers for angiogenesis included VEGF 165 (Invitrogen, Carlsbad, CA), VEGF-A (Ebioscience, San Diego, CA), soluble VEGFR (sVEGFR)-1 and sVEGFR-2 (Ebioscience), placental growth factor (PIGF; R&D Systems, Minneapolis, MN), interleukin 8 (IL-8; R&D Systems), basic fibroblast growth factor (bFGF; Invitrogen), and FGF23 (Millipore, Bedford, MA). All biomarkers were measured in duplicate at each time point and the average value of the two measurements was used for analysis.
BEAMing of ctDNA
Free circulating DNA was isolated from baseline serum samples using the QIAamp DNA purification kit (Qiagen). BEAMing assays were carried out on serum ctDNA samples for the detection of 29 KIT mutations (five in exon 11, one in exon 9, two in exon 13, two in exon 14, 18 in exon 17, and one in exon 18), five PDGFRα mutations, and one BRAF mutation (supplementary Table S1 , available at Annals of Oncology online). The details of the BEAMing methodology are described elsewhere [6] . BEAMing assays were conducted by Inostics GmbH (Hamburg, Germany).
statistical analysis
For each serum biomarker, the fold change from baseline to the end of the first cycle of dovitinib was calculated. The χ 2 test and Mann-Whitney U-test were used to assess the associations for categorical and continuous variables, respectively. The probability of survival was estimated using the 
results
Details of the clinical outcomes obtained with dovitinib were previously presented elsewhere [3] , and are summarized in the appendix. Historical mutational data from archival tumor tissues collected before entry into this trial were available for 28 patients; KIT exon 11, KIT exon 9, and PDGFRα exon 18 mutations were found in 20 (71%), 5 patients (18%), and 1 patient (4%), respectively. Figure S1 , available at Annals of Oncology online). Dovitinib increased the levels of VEGF 165 (1.26-fold, P = 0.006), VEGF-A (1.27-fold, P = 0.004), PIGF (6.0-fold, P = 0.002), FGF23 (1.45-fold, P = 0.02), and IL-8 (1.75-fold, P = 0.04), whereas sVEGFR-2 levels decreased 0.8-fold from baseline (P = 0.001).
serum protein biomarkers
For all six detectable proteins, baseline serum levels did not differ according to either metabolic response or 24-week DCR (P > 0.1 for all comparisons). However, a significantly larger decrease in sVEGFR-2 was observed in patients with metabolic PR than in those with metabolic SD or progressive disease (mean fold change, 0.63 versus 0.88; P = 0.02; Figure 1A ), although the change in sVEGFR-2 levels was not associated with 24-week DCR (P = 0.39). Changes in the other five serum proteins did not correlate with either metabolic response or 24-week DCR (P > 0.1 for all comparisons).
To examine correlations between serum biomarkers and PFS, patient groups were categorized according to their baseline levels and fold changes. Notably, the fold change in sVEGFR-2 concentration was significantly associated with PFS ( Figure 1B) . Patients with the greatest decrease in sVEGFR-2 levels {quartile [Q]1-Q3; median, 4.2 months [95% confidence interval (CI) 2.9-5.5 months]} following dovitinib treatment showed better PFS than those with smaller changes in sVEGFR-2 levels [Q4; 2.7 months (95% CI 0.4-5.0 months), HR = 0.4 (95% CI 0.1-0.9); P = 0.02]. Except for the change in sVEGFR-2, no correlation between serum biomarkers and PFS was observed.
genotyping of ctDNA analyzed for three patients due to insufficient serum sample volumes, all other mutations were assessed for all patients. The three patients without data for KIT exon 17 mutations in ctDNA were not included in the analysis for secondary mutations. BEAMing of serum ctDNA identified primary kinase mutations in five (17%) patients (two for KIT exon 11 and three for exon 9). These were 100% concordant with the results of mutation analyses from tumor tissue taken from the corresponding patients. Secondary kinase mutations were identified in 11 (41%) patients. Each of these patients had a mutation involving KIT exon 17. Three (27%) patients with KIT exon 11 mutations had more than one secondary KIT mutation (supplementary Table S2 , available at Annals of Oncology online). Except for patient age, none of the baseline patient characteristics examined was significantly associated with the presence of secondary KIT mutations ( Table 1) .
The results of correlation analyses between the secondary KIT mutations detected in serum ctDNA and the activity of dovitinib are summarized in Table 2 . Response rate, 24-week DCR, and metabolic response rate did not correlate with the presence of secondary serum ctDNA mutations. However, all four patients who achieved disease control by 24 weeks (including one patient with a PR) lacked secondary mutations, whereas tumors progressed within 24 weeks in all patients with secondary mutations. Figure 2 shows the relationship between survival outcomes and secondary mutations in serum ctDNA. Patients with secondary mutations had numerically shorter PFS [median 3.4 months (95% CI 2.2-4.6 months)] than those with no detectable secondary mutations [3.6 months (95% CI 2.6-4.6 months), HR = 1.7 (95% CI 0.7-3.9)], although this difference did not reach statistical significance (P = 0.23). OS was significantly worse in patients with secondary mutations [median 5.5 months (95% CI 3.8-7.2 months)] than in those who did not have secondary mutations [9.8 months (95% CI 9.6-10.0 months), HR = 2.7 (95% CI 1.0-7.3); P = 0.047].
In patients with secondary KIT mutations in serum ctDNA, baseline serum FGF23 levels [≤median (n = 5) versus >median (n = 6)] were significantly associated with PFS [median, 1.8 months (95% CI 0.8-2.8 months) versus 3.6 months (95% CI 3.2-4.0); P = 0.02; supplementary Figure S2A , available at 
discussion
Our results demonstrate that dovitinib has pharmacological effects on both the VEGFR and FGFR pathways. Although baseline levels of candidate serum biomarkers were not predictive, changes in sVEGFR-2 levels were associated with dovitinibmediated antitumor activity. Genotyping of serum ctDNA using novel BEAMing technology is a viable method for identifying resistant mutations in GISTs. Dovitinib modulates serum levels of circulating proteins associated with VEGFR and FGFR signaling. Dovitinib treatment increased VEGF 165 , VEGF-A, PIGF, and IL-8 levels and decreased sVEGFR2 levels, suggesting that dovitinib inhibited VEGF signaling in our patients. Consistent with previous studies [7] , dovitinib-mediated inhibition of FGFR signaling was associated with increased levels of FGF23. It has been suggested that increased FGF23 levels result from compensatory upregulation following FGFR1 inhibition [7] . This suggests that the soluble serum proteins tested in this study may be pharmacodynamic markers for dovitinib activity and may act as predictive biomarkers in patients treated with dovitinib.
The baseline levels of the serum protein biomarkers were not predictive of clinical response to dovitinib in these patients. However, changes in sVEGFR-2 levels were significantly associated with clinical outcome. There was a greater decrease in sVEGFR-2 levels in patients with a metabolic PR than those who had metabolic SD or progressive disease. Patients who experienced smaller decreases in sVEGFR-2 levels following dovitinib treatment had reduced PFS. Considering that the decrease in sVEGFR-2 levels reflects VEGFR inhibition, this result suggests that the magnitude of VEGFR inhibition may reflect the level of dovitinib activity. In line with this, previous studies on other anti-VEGFR TKIs also demonstrated that decreased sVEGFR-2 levels were associated with improved efficacy [8] . Therefore, changes in sVEGFR-2 concentration may have predictive value for patients treated with dovitinib.
The major mechanism of acquired resistance to imatinib is the development of secondary kinase mutations. These are found in 50%-70% of patients who experience disease progression [9] . Secondary mutations are also associated with clinical response to subsequent TKI therapy [10] . Therefore, identification of secondary mutations may help to guide more personalized therapy against GISTs. However, repeat biopsies and genotyping after progression are not widely accepted for the management of patients with TKI-resistant GISTs because tissue biopsies provide limited information on molecular heterogeneity, and approximately two thirds of these patients experience multiple mutations [11] . Moreover, the risk of procedure-related complications may outweigh any potential benefit of the additional biopsy, and tumor lesions may not always be accessible to biopsy. To overcome the limitations of tissue biopsy, the utility of ctDNA as a biomarker has been actively investigated [4] . With the introduction of highly sensitive techniques, including BEAMing, the clinical advantages of less invasive 'liquid biopsies' have become clear, particularly for advanced cancers characterized by molecular heterogeneity [4, 5] .
Our results showed that primary and secondary kinase mutations could be detected by genotyping serum-derived ctDNA from patients with TKI-refractory GISTs. Primary kinase mutations were identified in 17% of patients. As the BEAMing assay used in this study was not designed to detect most primary mutations, particularly those located in exon 11, the detection rate of primary mutations was relatively low, but the results of the mutation analysis from serum-derived ctDNA were 100% concordant with those derived from archival tumor tissue samples. Consistent with our results, in a subset analysis of a GRID trial for regorafenib in TKI-refractory GISTs [12] , BEAMing of plasma-derived ctDNA found primary mutations in 27% of analyzed cases, and the concordance rate between BEAMing of ctDNA and sequencing of tumor tissue was 84%.
Secondary KIT mutations were found in the serum-derived ctDNA of 41% (11 of 27) of patients; 27% (3 of 11) of these cases had more than one KIT mutation. All patients with secondary KIT mutations in ctDNA had mutations involving the activation loop domain (exons 17 or 18). One patient (9%) had mutations present in both the ATP/drug-binding pocket (exons 13 and 14) and the activation loop domain. Consistent with our results, in the GRID trial, secondary KIT mutations were detected in 47% of patients; of these, KIT mutations were detected in exon 17/18 and 13/14 in 64% and 25% of patients, respectively, and 12% had mutations present in both domains [12] . The results of these two studies showed that secondary mutations are readily detectable in ctDNA by BEAMing and the majority of these mutations are located in the activation loop.
The presence of secondary KIT mutations in serum-derived ctDNA was significantly associated with reduced OS. This finding is supported by the results of a recent preclinical study that showed that dovitinib had limited activity against imatinibrefractory GIST cell lines harboring secondary KIT mutations (in exon 17 and 13) [13] . These results indicate that the detection of secondary mutations in ctDNA may be a promising tool for predicting drug efficacy and prognosis in patients with TKIresistant GISTs. This also may be a useful enrichment strategy for future clinical trials of novel agents specifically targeting secondary mutations. Furthermore, baseline FGF23 levels and changes in sVEGFR-2 levels were associated with PFS in patients with secondary mutations. However, there was no correlation between the serum biomarkers examined and PFS in those patients where secondary mutations were not detected. This should be interpreted with caution, as only a small number of patients were included in the analysis. Nevertheless, our results suggest that dovitinib-mediated inhibition of the FGFR and VEGFR pathways may contribute to drug efficacy in patients with resistance mutations. However, the role of VEGFR and FGFR inhibition has not been established in the treatment of GISTs and remains to be defined in future studies.
Despite promising results using BEAMing for the detection of mutations in ctDNA, a major limitation of BEAMing is that it can only detect known mutations specifically included in the assay, and therefore cannot identify novel mutations or those not included in the assay. Optimal target mutation profiling for BEAMing of ctDNA and novel methodology, such as single-cell next-generation sequencing, are needed to overcome these limitations.
In conclusion, our analysis demonstrated that soluble serum proteins and secondary KIT mutations identified in serumderived ctDNA are promising biomarkers for TKI-refractory GISTs. Further investigations of the clinical implications of soluble serum biomarkers and mutation analysis using serumderived ctDNA are needed to validate these findings in a large patient population. 
